Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2007 3
2009 2
2010 1
2014 3
2015 3
2016 2
2017 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Hanna N, et al. J Clin Oncol. 2004 May 1;22(9):1589-97. doi: 10.1200/JCO.2004.08.163. J Clin Oncol. 2004. PMID: 15117980 Corrected and republished. Clinical Trial.
PATIENTS AND METHODS: Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced NSCLC, and adequate organ function. Patients received pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with vitamin B(12), folic ac …
PATIENTS AND METHODS: Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced …
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TCY, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Hanna N, et al. J Clin Oncol. 2023 May 20;41(15):2682-2690. doi: 10.1200/JCO.22.02546. J Clin Oncol. 2023. PMID: 37196429
PATIENTS AND METHODS: Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced NSCLC, and adequate organ function. Patients received pemetrexed 500 mg/m(2) intravenously (IV) day 1 with vitamin B(12), folic acid …
PATIENTS AND METHODS: Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced …
Pyrazoline bearing benzimidazoles: search for anticancer agent.
Shaharyar M, Abdullah MM, Bakht MA, Majeed J. Shaharyar M, et al. Eur J Med Chem. 2010 Jan;45(1):114-9. doi: 10.1016/j.ejmech.2009.09.032. Epub 2009 Sep 23. Eur J Med Chem. 2010. PMID: 19883957
Among the synthesize compounds, six compounds were granted NSC code and screened at National Cancer Institute (NCI), USA for anticancer activity at a single high dose (10(-5) M) in full NCI 60 cell panel. Among the selected compounds, (4f) 2-[5-(3,4-dimethoxyphenyl)-1-phen …
Among the synthesize compounds, six compounds were granted NSC code and screened at National Cancer Institute (NCI), USA for anticancer acti …
Anti-inflammatory effect of cinnamaldehyde in Helicobacter pylori induced gastric inflammation.
Muhammad JS, Zaidi SF, Shaharyar S, Refaat A, Usmanghani K, Saiki I, Sugiyama T. Muhammad JS, et al. Biol Pharm Bull. 2015;38(1):109-15. doi: 10.1248/bpb.b14-00609. Biol Pharm Bull. 2015. PMID: 25744466 Free article.
The effect on activation of nuclear factor kappa B (NF-kappaB) was determined by immunoblot analysis. The non-cytotoxic CM (125 M) was also non-bactericidal at the given time, suggesting the effect in H. pylori/cell co-culture system was not due to alteration in H. pylori …
The effect on activation of nuclear factor kappa B (NF-kappaB) was determined by immunoblot analysis. The non-cytotoxic CM (125 M) wa …
Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.
Rathore A, Rahman MU, Siddiqui AA, Ali A, Shaharyar M. Rathore A, et al. Arch Pharm (Weinheim). 2014 Dec;347(12):923-35. doi: 10.1002/ardp.201400219. Epub 2014 Oct 9. Arch Pharm (Weinheim). 2014. PMID: 25303727
The synthesized compounds were screened by in vitro cyclooxygenase assays to determine COX-1 and COX-2 inhibitory potency and the results showed that they had good-to-remarkable activity with an IC50 range of 11.6-56.1 M. The most active compounds were further screened for …
The synthesized compounds were screened by in vitro cyclooxygenase assays to determine COX-1 and COX-2 inhibitory potency and the results sh …
Anticancer activity of new compounds using benzimidazole as a scaffold.
Rashid M, Husain A, Shaharyar M, Sarafroz M. Rashid M, et al. Anticancer Agents Med Chem. 2014;14(7):1003-18. doi: 10.2174/1871520614666140509153021. Anticancer Agents Med Chem. 2014. PMID: 24827531
The title compound 3e (NSC: 765733/1) exhibited notable growth inhibition that satisfies threshold criteria at single dose (10 M) on all human cell lines of NCI. This compound was considered for further study at five dose levels (0.01, 0.1, 1, 10 and 100 M) with GI5 …
The title compound 3e (NSC: 765733/1) exhibited notable growth inhibition that satisfies threshold criteria at single dose (10 M) on …
An Extremely Rare Manifestation of Multiple Myeloma: An Immunoglobulin D Secreting Testicular Plasmacytoma.
Sharma A, Binazir T, Sintow A, Lee CC, Shaharyar S, Tache J. Sharma A, et al. Cureus. 2017 Jun 27;9(6):e1400. doi: 10.7759/cureus.1400. Cureus. 2017. PMID: 28845377 Free PMC article.
It can present a diagnostic challenge because of the low amount of immunoglobulin in the serum. The amount of monoclonal (M)-protein is often undetectable on electrophoresis. Historically, survival in these patients was typically shorter compared to the immunoglobulin A (I …
It can present a diagnostic challenge because of the low amount of immunoglobulin in the serum. The amount of monoclonal (M)-protein …
Lymphocyte/monocyte ratio in osteoarticular tuberculosis in children: a haematological biomarker revisited.
Agarwal A, Bhat MS, Kumar A, Shaharyar A, Mishra M, Yadav R. Agarwal A, et al. Trop Doct. 2016 Apr;46(2):73-7. doi: 10.1177/0049475515609244. Epub 2015 Oct 25. Trop Doct. 2016. PMID: 26503639
Haemoglobin, total leucocyte, monocyte and lymphocyte count, and erythrocyte sedimentation rate (ESR) were collected at 0, 2 and 6 months, and were analysed. RESULTS: The L/M ratio altered from high (11) at the start of treatment towards normalisation (9) at 2 months and ( …
Haemoglobin, total leucocyte, monocyte and lymphocyte count, and erythrocyte sedimentation rate (ESR) were collected at 0, 2 and 6 months, a …
Oxadiazole mannich bases: synthesis and antimycobacterial activity.
Ali MA, Shaharyar M. Ali MA, et al. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3314-6. doi: 10.1016/j.bmcl.2007.04.004. Epub 2007 Apr 6. Bioorg Med Chem Lett. 2007. PMID: 17467984
The synthesized compounds were evaluated for antimycobacterial activity against M. tuberculosis H(37)Rv and INH resistant M. tuberculosis. Among the synthesized compounds, compound (4) 3-{2-furyl[4-(4-{2-furyl[5-(2-naphthyloxymethyl)-2-thioxo-2,3-dihydro-1,3,4-oxadi …
The synthesized compounds were evaluated for antimycobacterial activity against M. tuberculosis H(37)Rv and INH resistant M. t …
The Effectiveness of a Worksite Lifestyle Intervention Program on High-Risk Individuals as Potential Candidates for Bariatric Surgery: My Unlimited Potential (MyUP).
Osondu CU, Aneni EC, Shaharyar S, Roberson L, Rouseff M, Das S, Spatz E, Younus A, Guzman H, Brown D, Santiago-Charles J, Ochoa T, Mora J, Gilliam C, Lehn V, Sherriff S, Tran T, Gonzalez A, Virani S, Feldman T, Agatston AS, Nasir K. Osondu CU, et al. Popul Health Manag. 2016 Oct;19(5):368-75. doi: 10.1089/pop.2015.0111. Epub 2016 Jan 13. Popul Health Manag. 2016. PMID: 26760281
Employees of Baptist Health South Florida were considered eligible to participate if they had 2 or more of the following cardiometabolic risk factors: total cholesterol 200 mg/dL, systolic blood pressure 140 mmHg or diastolic blood pressure 90 mmHg, hemoglobin A1c 6.5%, body mass …
Employees of Baptist Health South Florida were considered eligible to participate if they had 2 or more of the following cardiometabolic ris …
16 results